Analytical Development and Quality Research

Analytical development and quality research provide the analytical foundation for understanding, evaluating, and controlling the quality of drug substances and drug products throughout pharmaceutical development. Protheragen provides integrated analytical services covering analytical method development, method validation, release testing, stability research, and impurity-related studies to support product characterization, quality assessment, and CMC development.

Overview of Analytical Development and Quality Research

Analytical development and quality research encompasses a range of scientific activities used to characterize pharmaceutical materials, establish suitable analytical procedures, monitor product quality, and investigate quality changes throughout the development lifecycle. Analytical method development focuses on establishing appropriate procedures for measuring critical quality attributes, while method validation evaluates whether analytical procedures are suitable for their intended purpose.

Quality research also extends beyond routine analytical testing. Stability studies assess changes in product quality under defined storage and stress conditions, while impurity research focuses on the detection, identification, characterization, and control of process-related impurities and degradation products. Together, these activities generate analytical data that can support process development, quality control, specification development, stability assessment, impurity control, and regulatory CMC requirements.

Fig.1 Techniques and Instrumentation in Analytical Methods. (Patil M, et al., 2024)

Our Services

Protheragen organizes analytical and quality research into three closely connected service areas:

Integrated Analytical Development Workflow

A coordinated workflow connects analytical development with quality evaluation, stability assessment, and impurity research. This approach allows analytical strategies to evolve with product and process development requirements.

Analytical Support Throughout the CMC Lifecycle

Analytical requirements change as pharmaceutical product progresses from early development to commercialization. Analytical strategies can therefore be adjusted according to the development stage, product characteristics, process changes, and quality objectives.

Key Analytical & Quality Research Capabilities

• Assay & Related Substances

Analytical procedures support quantitative determination of assay and related substances to evaluate the strength, purity, and overall quality of drug substances and drug products.

• Impurity & Degradation Product Research

Impurity profiling and degradation studies help identify process-related impurities, degradation products, and potentially significant unknown components for further characterization and control.

• Genotoxic Impurity Analysis

Sensitive analytical approaches can be applied to the detection and quantification of potentially genotoxic impurities to support risk assessment and impurity control.

• Residual Solvent & Elemental Impurity Testing

Testing for residual solvents and elemental impurities provides additional quality information and supports impurity monitoring and control in pharmaceutical materials and products.

• Stability-Indicating Analytical Methods

Analytical procedures are developed or optimized to distinguish relevant degradation products from the active ingredient and other product components during stability and forced degradation studies.

• Physicochemical Characterization

Appropriate analytical techniques are used to evaluate physicochemical properties relevant to product quality, process development, and formulation performance.

Analytical Method Development for Pharmaceutical Quality Control

Analytical method development establishes suitable procedures for measuring critical quality attributes and supporting product and process understanding. Method selection and optimization take into account product characteristics, analytical objectives, expected impurities, sample matrix, and intended use.

The analytical strategy can be adapted from early-stage characterization and process development to validated methods for quality control and release testing. This lifecycle-oriented approach supports method reliability and practical application throughout pharmaceutical development and is aligned with the principles of ICH Q14 and ICH Q2(R2).

Why Choose Protheragen

• Integrated Analytical Capabilities

Method development, validation, release testing, stability research, and impurity investigation are coordinated within an integrated analytical and CMC framework.

• Development-Stage Flexibility

Analytical strategies can be tailored to the development stage, product characteristics, testing objectives, and evolving quality requirements.

• Risk-Based Analytical Approach

Analytical development focuses on critical quality attributes, potential impurities, degradation risks, and other factors that may affect product quality.

• Cross-Functional CMC Support

Analytical research can be integrated with preformulation, process development, formulation development, stability studies, and impurity control.

• Data-Driven Quality Assessment

Analytical, stability, and impurity data are evaluated to support method optimization, quality assessment, specification development, and control strategy decisions.

Whether the project requires analytical method development, method validation, pharmaceutical release testing, stability studies, impurity identification, or broader CMC analytical support, Protheragen provides integrated analytical development and quality research services tailored to product and development-stage requirements. Contact us to discuss your analytical development and quality research needs.